Randomized trial · people

MK-677: IGF-I rose 52% at 10 mg and 79% at 50 mg in GH-deficient men

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a small, short trial of men with severe GH deficiency, MK-677 raised GH and IGF-I but also raised insulin and blood sugar, and the GH rise was largest in the men who were least deficient at the start.

Kind
Randomized trial
Studied in
People
Number studied
9
Published
1997
Journal
J Clin Endocrinol Metab

What they tested

Can daily oral MK-677 raise growth hormone (GH) and IGF-I, a hormone made in response to GH, in adults with severe GH deficiency?

How the study was done

A small double-blind randomized trial in 9 men aged 17-34 with severe GH deficiency who had been treated with GH as children, using a rising-dose design over two 4-day treatment periods at least 28 days apart. One group took placebo and 10 mg a day of MK-677 in crossover order, and the other took 10 mg a day and then 50 mg a day.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking MK-677? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

IGF-I and 24-hour average GH rose in every man on both doses compared with his own starting levels. In the 10 mg arm, IGF-I rose 52% (65 to 99 micrograms/L) and 24-hour average GH rose 79% (0.14 to 0.26 microgram/L). In the 50 mg arm, IGF-I rose 79% (84 to 150 micrograms/L) and 24-hour average GH rose 82% (0.21 to 0.39 microgram/L), and IGFBP-3, a protein that carries IGF-I in the blood, rose on both doses. MK-677 was generally well tolerated with no significant change in cortisol, prolactin or thyroid hormones, but fasting and after-meal insulin and after-meal glucose went up significantly.

What it doesn’t show

This was a very small study with only 4-day treatment periods, and most results were compared with each man's own starting levels, with no placebo comparison for the 50 mg dose. The rise in insulin and glucose needs longer studies to judge whether it matters.

The paper

Chapman et al. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. J Clin Endocrinol Metab. 1997.

The compound

More studies on MK-677

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking MK-677? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo